Results from a phase 3 clinical trial, recently published in The Lancet Oncology, present a significant breakthrough in the field of prostate cancer surgery. The NeuroSAFE technique, a novel approach ...

Low-intensity extracorporeal shock wave therapy (LI-SWT) did not improve erectile dysfunction compared to a sham procedure in radical prostatectomy patients. Fewer than 20% of men in the LI-SWT group ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after ...

Testosterone testing and treatment have increased significantly over the past 2 decades, yet clinical practices remain inconsistent. 1,2 Despite rising awareness and prescription trends, up to 25% of ...

In continuation of last week’s essay, Type 2 is the most common type of ED in men under 45. It is also the only type that has ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...